Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 15;36(18):2670-2683.
doi: 10.15252/embj.201797135. Epub 2017 Aug 7.

Modulating NAD+ metabolism, from bench to bedside

Affiliations
Review

Modulating NAD+ metabolism, from bench to bedside

Elena Katsyuba et al. EMBO J. .

Abstract

Discovered in the beginning of the 20th century, nicotinamide adenine dinucleotide (NAD+) has evolved from a simple oxidoreductase cofactor to being an essential cosubstrate for a wide range of regulatory proteins that include the sirtuin family of NAD+-dependent protein deacylases, widely recognized regulators of metabolic function and longevity. Altered NAD+ metabolism is associated with aging and many pathological conditions, such as metabolic diseases and disorders of the muscular and neuronal systems. Conversely, increased NAD+ levels have shown to be beneficial in a broad spectrum of diseases. Here, we review the fundamental aspects of NAD+ biochemistry and metabolism and discuss how boosting NAD+ content can help ameliorate mitochondrial homeostasis and as such improve healthspan and lifespan.

Keywords: aging; metabolic disorders; neurodegeneration; nicotinamide adenine dinucleotide; poly ADP‐ribose polymerase.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Pathways modulating NAD+ content in mammals
Intermediates of the amidated and deamidated routes are depicted in yellow and green, respectively. NAD +‐consuming enzymes competing with sirtuins for NAD + availability are depicted in orange. Purple color indicates metabolites not recycled in the NAD + synthesis pathway.
Figure 2
Figure 2. Therapeutic potential of NAD + boosting in humans based on findings in animal studies
NAFLD, non‐alcoholic fatty liver disease; AFLD, alcoholic fatty liver disease.

References

    1. Agrimi G, Brambilla L, Frascotti G, Pisano I, Porro D, Vai M, Palmieri L (2011) Deletion or overexpression of mitochondrial NAD+ carriers in Saccharomyces cerevisiae alters cellular NAD and ATP contents and affects mitochondrial metabolism and the rate of glycolysis. Appl Environ Microbiol 77: 2239–2246 - PMC - PubMed
    1. Aksoy S, Szumlanski CL, Weinshilboum RM (1994) Human liver nicotinamide N‐methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem 269: 14835–14840 - PubMed
    1. Aksoy P, Escande C, White TA, Thompson M, Soares S, Benech JC, Chini EN (2006a) Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem Biophys Res Comm 349: 353–359 - PubMed
    1. Aksoy P, White TA, Thompson M, Chini EN (2006b) Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Comm 345: 1386–1392 - PubMed
    1. Alano CC, Ying W, Swanson RA (2004) Poly(ADP‐ribose) polymerase‐1‐mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. J Biol Chem 279: 18895–18902 - PubMed

Publication types